Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia.
Syrykh C, Pons-Brun B, Russiñol N, Playa-Albinyana H, Baumann T, Duran-Ferrer M, Kulis M, Carbó-Meix A, Mozas P, Alcoceba M, González M, Navarro-Bailón A, Colado E, Payer ÁR, Aymerich M, Terol MJ, Lu J, Knisbacher BA, Hahn CK, Ruiz-Gaspà S, Enjuanes A, Wu CJ, Getz G, Zenz T, López-Guillermo A, Martín-Subero JI, Colomer D, Delgado J, Campo E, Nadeu F. Syrykh C, et al. Among authors: mozas p. Blood Adv. 2023 Dec 12;7(23):7384-7391. doi: 10.1182/bloodadvances.2023010132. Blood Adv. 2023. PMID: 37505099 Free PMC article. No abstract available.
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E. Delgado J, et al. Among authors: mozas p. Am J Hematol. 2017 Apr;92(4):375-380. doi: 10.1002/ajh.24660. Epub 2017 Feb 13. Am J Hematol. 2017. PMID: 28120419 Free article.
Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?
Ortiz-Maldonado V, Villamor N, Baumann T, Aymerich M, Magnano L, Mozas P, Rivas-Delgado A, Martínez-Trillos A, Giné E, Campo E, López-Guillermo A, Delgado J. Ortiz-Maldonado V, et al. Among authors: mozas p. Br J Haematol. 2018 Oct;183(1):127-129. doi: 10.1111/bjh.14900. Epub 2017 Aug 18. Br J Haematol. 2018. PMID: 28832940 Free article. No abstract available.
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.
Rivas-Delgado A, Magnano L, Moreno-Velázquez M, García O, Nadeu F, Mozas P, Dlouhy I, Baumann T, Rovira J, González-Farre B, Martínez A, Balague O, Delgado J, Villamor N, Giné E, Campo E, Sancho-Cia JM, López-Guillermo A. Rivas-Delgado A, et al. Among authors: mozas p. Br J Haematol. 2019 Mar;184(5):753-759. doi: 10.1111/bjh.15708. Epub 2018 Dec 4. Br J Haematol. 2019. PMID: 30515755 Free article. Clinical Trial.
Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience.
Mozas P, Nadeu F, Rivas-Delgado A, Rivero A, Garrote M, Balagué O, González-Farré B, Veloza L, Baumann T, Giné E, Delgado J, Villamor N, Campo E, Magnano L, López-Guillermo A. Mozas P, et al. Blood Cancer J. 2020 Mar 5;10(3):31. doi: 10.1038/s41408-020-0299-0. Blood Cancer J. 2020. PMID: 32139690 Free PMC article.
High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era.
Mozas P, Rivas-Delgado A, Rivero A, Dlouhy I, Nadeu F, Balagué O, González-Farré B, Baumann T, Giné E, Delgado J, Villamor N, Campo E, Pérez-Galán P, Filella X, Magnano L, López-Guillermo A. Mozas P, et al. Leuk Res. 2020 Jul;94:106371. doi: 10.1016/j.leukres.2020.106371. Epub 2020 May 19. Leuk Res. 2020. PMID: 32473488 Clinical Trial.
A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma.
Mozas P, Rivero A, Rivas-Delgado A, Nadeu F, Clot G, Correa JG, Castillo C, Bataller A, Baumann T, Giné E, Delgado J, Villamor N, Campo E, Pérez-Galán P, Magnano L, López-Guillermo A. Mozas P, et al. Leuk Lymphoma. 2021 Jan;62(1):104-111. doi: 10.1080/10428194.2020.1821010. Epub 2020 Sep 19. Leuk Lymphoma. 2021. PMID: 32954916
66 results